Overall survival in patients with malignant glioma may be significantly longer with tumors located in deep grey matter

Journal of the Neurological Sciences

Volumn 260, Issue 1-2, 2007, Pages 49-56

  Ramnarayan, Ramachandran ^a   Dodd, Susanna ^b   Das, Kumar ^a   Heidecke, Volkmar ^c,d   Rainov, Nikolai G ^c,d  

^a WALTON CENTRE FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c KLINIKUM AUGSBURG   (Germany)

^d MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Anaplastic astrocytoma; Brain; Deep grey matter; Glioblastoma; Glioma; White matter

Indexed keywords

ADULT; AGED; ARTICLE; BRAIN EDEMA; CANCER GRADING; CANCER LOCALIZATION; CANCER SURVIVAL; FEMALE; GLIOBLASTOMA; GRAY MATTER; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RISK FACTOR; SURVIVAL TIME; WHITE MATTER;

ADOLESCENT; ADULT; AGED; ASTROCYTOMA; BRAIN; BRAIN NEOPLASMS; CHILD; DISEASE PROGRESSION; FEMALE; GLIOMA; GREAT BRITAIN; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NERVE FIBERS, MYELINATED; PROGNOSIS; REGRESSION ANALYSIS; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 34547676017     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2007.04.003     Document Type: Article

References (35)

1. Ohgaki H., and Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 64 (2005) 479-489
2. In: Kleihues P., and Cavenee W.K. (Eds). Pathology and genetics of tumors of the nervous system. WHO classification of tumours. Pathology and genetics (2000), IARC Press, Lyon
3. Salcman M. Malignant glioma management. Neurosurg Clin N Am 1 (1990) 49-63
4. Schiffer D., Cavalla P., Dutto A., and Borsotti L. Cell proliferation and invasion in malignant gliomas. Anticancer Res 17 (1997) 61-69
5. Swanson K.R., Alvord Jr. E.C., and Murray J.D. Virtual brain tumours (gliomas) enhance the reality of medical imaging and highlight inadequacies of current therapy. Br J Cancer 86 (2002) 14-18
6. Mitchell P., Ellison D.W., and Mendelow A.D. Surgery for malignant gliomas: mechanistic reasoning and slippery statistics. Lancet Neurol 4 (2005) 413-422
7. Burton E.C., and Prados M.D. Malignant gliomas. Curr Treat Options Oncol 1 (2000) 459-468
8. Whittle I.R. Surgery for gliomas. Curr Opin Neurol 15 (2002) 663-669
9. Hess C.F., Schaaf J.C., Kortmann R.D., Schabet M., and Bamberg M. Malignant glioma: patterns of failure following individually tailored limited volume irradiation. Radiother Oncol 30 (1994) 146-149
10. Chang S.M., Parney I.F., Huang W., Anderson Jr. F.A., Asher A.L., Bernstein M., et al. Glioma outcomes investigators: survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J Neurosurg 99 (2003) 467-473
11. Swanson K.R., Bridge C., Murray J.D., and Alvord Jr. E.C. Virtual and real brain tumors: using mathematical modeling to quantify glioma growth and invasion. J Neurol Sci 216 (2003) 1-10
12. Swanson K.R., Alvord Jr. E.C., and Murray J.D. A quantitative model for differential motility of gliomas in grey and white matter. Cell Prolif 33 (2000) 317-329
13. Woodward D.E., Cook J., Tracqui P., Cruywagen G.C., Murray J.D., and Alvord Jr. E.C. A mathematical model of glioma growth: the effect of extent of surgical resection. Cell Prolif 29 (1996) 269-288
14. Tracqui P. From passive diffusion to active cellular migration in mathematical models of tumour invasion. Acta Biotheor 43 (1995) 443-464
15. Wallner K.E., Galicich J.H., Krol G., Arbit E., and Malkin M.G. Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 16 (1989) 1405-1409
16. Lee S.W., Fraass B.A., Marsh L.H., Herbort K., Gebarski S.S., Martel M.K., et al. Patterns of failure following high-dose 3-D conformal radiotherapy for high-grade astrocytomas: a quantitative dosimetric study. Int J Radiat Oncol Biol Phys 43 (1999) 79-88
17. Quigley M.R., and Maroon J.C. The relationship between survival and the extent of resection in patients with supratentorial malignant gliomas. Neurosurgery 29 (1991) 385-388
18. Schiff D., and Shaffrey M.E. Role of resection for newly diagnosed malignant gliomas. Expert Rev Anticancer Ther 3 (2003) 621-630
19. Vuorinen V., Hinkka S., Farkkila M., and Jaaskelainen J. Debulking or biopsy of malignant glioma in elderly people - a randomised study. Acta Neurochir 145 (2003) 5-10
20. Grant R., and Metcalfe S.E. Biopsy versus resection for malignant glioma. Cochrane Database Syst Rev 2 (2005) CD002034
21. Hess K.R. Extent of resection as a prognostic variable in the treatment of gliomas. J Neurooncol 42 (1999) 227-231
22. Stummer W., Pichlmeier U., Meinel T., Wiestler O.D., Zanella F., and Reulen H.J. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 7 (2006) 392-401
23. Beks J.W., Bouma G.J., and Journee H.L. Tumours of the thalamic region. A retrospective study of 27 cases. Acta Neurochir 85 (1987) 125-127
24. Pathy S., Jayalakshmi S., Chander S., Singh R., Julka P.K., and Rath G.K. Prognostic factors influencing the outcome of thalamic glioma. Neurol India 50 (2002) 37-40
25. Grigsby P.W., Thomas P.R., Schwartz H.G., and Fineberg B.B. Multivariate analysis of prognostic factors in pediatric and adult thalamic and brainstem tumours. Int J Radiat Oncol Biol Phys 16 (1989) 649-655
26. Steiger H.J., Gotz C., Schmid-Elsaesser R., and Stummer W. Thalamic astrocytomas: surgical anatomy and results of a pilot series using maximum microsurgical removal. Acta Neurochir 142 (2000) 1327-1337
27. Nishio S., Morioka T., Suzuki S., Takeshita I., and Fukui M. Thalamic gliomas: a clinicopathologic analysis of 20 cases with reference to patient age. Acta Neurochir 139 (1997) 336-342
28. Tracqui P., Cruywagen G.C., Woodward D.E., Bartoo G.T., Murray J.D., and Alvord Jr. E.C. A mathematical model of glioma growth: the effect of chemotherapy on spatio-temporal growth. Cell Prolif 28 (1995) 17-31
29. Burgess P.K., Kulesa M., Murray J.D., and Alvord Jr. E.C. The interaction of growth rates and diffusion coefficients in a three-dimensional mathematical model of gliomas. J Neuropathol Exp Neurol 56 (1997) 704-713
30. Polin R.S., Marko N.F., Ammerman M.D., Shaffrey M.E., Huang W., Anderson Jr. F.A., et al. Functional outcomes and survival in patients with high-grade gliomas in dominant and nondominant hemispheres. J Neurosurg 102 (2005) 276-283
31. Wick W., and Kuker W. Brain edema in neurooncology: radiological assessment and management. Onkologie 27 (2004) 261-266
32. Hammoud M.A., Sawaya R., Shi W., Thall P.F., and Leeds N.E. Prognostic significance of preoperative MRI scans in glioblastoma multiforme. J Neurooncol 27 (1996) 65-73
33. Gamburg E.S., Regine W.F., Patchell R.A., Strottmann J.M., Mohiuddin M., and Young A.B. The prognostic significance of midline shift at presentation on survival in patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys 48 (2000) 1359-1362
34. Kreth F.W., Berlis A., Spiropoulou V., Faist M., Scheremet R., Rossner R., et al. The role of tumor resection in the treatment of glioblastoma multiforme in adults. Cancer 86 (1999) 2117-2123
35. Mandonnet E., Delattre J.Y., Tanguy M.L., Swanson K.R., Carpentier A.F., Duffau H., et al. Continuous growth of mean tumor diameter in a subset of grade II gliomas. Ann Neurol 53 (2003) 524-528